{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:48Z","timestamp":1753892088382,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To explore the risk factors for the reactivate of retinopathy of prematurity (ROP) after intravitreal injection of anti-vascular endothelial growth factor (VEGF) and to construct a nomogram model to predict the risk of ROP reactivate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on 185 ROP children who underwent anti-VEGF treatment at the First Affiliated Hospital of Zhengzhou University from January 2017 to October 2023. They were randomly divided into a training set (129 cases) and a validation set (56 cases) at a ratio of 7:3. The training set was further divided into a reactivate group (<jats:italic>n<\/jats:italic>\u2009=\u200918) and a non-reactivate group (<jats:italic>n<\/jats:italic>\u2009=\u2009111) based on whether ROP recurred after treatment. Multivariable logistic regression analysis was used to screen for risk factors for ROP reactivate. A nomogram model was constructed using R software and validated using the validation set. The discrimination, calibration, and clinical net benefit of the model were evaluated using the receiver operating characteristic curve (ROC curve), calibration curve, and decision curve analysis, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multivariable logistic regression analysis showed that the number of red blood cell transfusions, use of pulmonary surfactant (PS) 2 times or more, and preoperative fundus hemorrhage were independent risk factors for ROP reactivate (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). The area under the ROC curve (AUC) of the training set was 0.810 (95% CI: 0.706\u20130.914), and that of the validation set was 0.756 (95% CI: 0.639\u20130.873). The Hosmer-Leme show goodness-of-fit test indicated a good fit of the model (<jats:italic>P<\/jats:italic>\u2009=\u20090.31). Calibration curve analysis and decision curve analysis suggested high predictive efficacy and clinical application value of the model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The number of red blood cell transfusions, use of PS 2 times or more, and preoperative fundus hemorrhage are independent risk factors for ROP reactivate. The nomogram model constructed based on these factors has high predictive efficacy and clinical application value.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1440437","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:19:27Z","timestamp":1736234367000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Construction of a nomogram model to predict the risk of retinopathy of prematurity reactivate after intravitreal anti-vascular endothelial growth factor therapy: a retrospective study"],"prefix":"10.3389","volume":"12","author":[{"given":"Ziyun","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiantian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuyong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101230","DOI":"10.1016\/j.preteyeres.2023.101230","article-title":"Neonatal sepsis as a cause of retinopathy of prematurity: an etiological explanation","volume":"98","author":"Dammann","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1111\/apa.15197","article-title":"Higher incidence of retinopathy of prematurity in extremely preterm infants associated with improved survival rates","volume":"109","author":"Taner","year":"2020","journal-title":"Acta Paediatr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"101208","DOI":"10.1016\/j.preteyeres.2023.101208","article-title":"Identification of novel biomarkers for retinopathy of prematurity in preterm infants by use of innovative technologies and artificial intelligence","volume":"97","author":"Hoyek","year":"2023","journal-title":"Prog Retin Eye Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ajo.2023.09.004","article-title":"Validation of a published model to reduce burden of retinopathy of prematurity screening","volume":"257","author":"Pruett","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1051\/medsci\/2020163","article-title":"[Retinopathy of prematurity: from prevention to treatment]","volume":"36","author":"Daruich","year":"2020","journal-title":"Med Sci (Paris)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1055\/s-0040-1713181","article-title":"Update in the treatment of retinopathy of prematurity","volume":"39","author":"Bancalari","year":"2022","journal-title":"Am J Perinatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/ICU.0000000000000786","article-title":"Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy","volume":"32","author":"Valikodath","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3928\/15428877-20070501-09","article-title":"Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity","volume":"38","author":"Travassos","year":"2007","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"B9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/APO.0000000000000302","article-title":"Update on anti-vascular endothelial growth factor safety for retinopathy of prematurity","volume":"9","author":"Enriquez","year":"2020","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","article-title":"Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor","volume":"218","author":"Hartnett","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"897869","DOI":"10.3389\/fphar.2022.897869","article-title":"Effect of ranibizumab on retinopathy of prematurity: a meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang","year":"2021","journal-title":"Ophthalmology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and Laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"15647","DOI":"10.1038\/s41598-024-66483-2","article-title":"Characteristics of retinal vascularization in reactivated retinopathy of prematurity requiring treatment and clinical outcome after reinjection of ranibizumab","volume":"14","author":"Jang","year":"2024","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.survophthal.2018.04.002","article-title":"Retinopathy of prematurity: a review of risk factors and their clinical significance","volume":"63","author":"Kim","year":"2018","journal-title":"Surv Ophthalmol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaapos.2023.09.001","article-title":"Exudative retinal detachment after laser in retinopathy of prematurity","volume":"27","author":"Blair","year":"2023","journal-title":"J AAPOS"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1038\/s41433-023-02559-z","article-title":"Comparison of long-term treatment outcomes of laser and anti-VEGF therapy in retinopathy of prematurity: a multicentre study from J-CREST group","volume":"37","author":"Murakami","year":"2023","journal-title":"Eye (Lond)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen","year":"2023","journal-title":"Ital J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s10792-022-02615-9","article-title":"One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity","volume":"43","author":"Kiran Yenice","year":"2023","journal-title":"Int Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10792-022-02480-6","article-title":"Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review","volume":"43","author":"Tsiropoulos","year":"2023","journal-title":"Int Ophthalmol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00417-020-04605-y","article-title":"A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series","volume":"258","author":"Mart\u00ednez-Castellanos","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s10792-021-02188-z","article-title":"Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment","volume":"42","author":"Suren","year":"2022","journal-title":"Int Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaophthalmol.2019.2442","article-title":"A quantitative severity scale for retinopathy of prematurity using deep learning to monitor disease regression after treatment","volume":"137","author":"Gupta","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/jama.2020.10690","article-title":"Effects of liberal vs restrictive transfusion thresholds on survival and neurocognitive outcomes in extremely low-birth-weight infants: the ETTNO randomized clinical trial","volume":"324","author":"Franz","year":"2020","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1111\/apa.16965","article-title":"Erythrocyte transfusions are associated with retinopathy of prematurity in extremely low gestational age newborns","volume":"112","author":"Glaser","year":"2023","journal-title":"Acta Paediatr"},{"key":"B28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5409\/wjcp.v3.i3.19","article-title":"Transfusion related morbidity in premature babies: possible mechanisms and implications for practice","volume":"3","author":"Collard","year":"2014","journal-title":"World J Clin Pediatr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.4103\/IJO.IJO_692_23","article-title":"Fetal hemoglobin, blood transfusion, and retinopathy of prematurity in preterm infants: an observational, prospective study","volume":"71","author":"Prasad","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1136\/fn.84.3.F188","article-title":"Blood transfusion increases radical promoting non-transferrin bound iron in preterm infants","volume":"84","author":"Hirano","year":"2001","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"B31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood.V100.3.879","article-title":"Pro-oxidant and cytotoxic effects of circulating heme","volume":"100","author":"Jeney","year":"2002","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41372-020-00779-9","article-title":"Characteristics and outcomes of preterm neonates according to number of doses of surfactant received","volume":"41","author":"Coshal","year":"2021","journal-title":"J Perinatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4103\/0301-4738.62644","article-title":"Results of screening for retinopathy of prematurity in a large nursery in Kuwait: incidence and risk factors","volume":"58","author":"Wani","year":"2010","journal-title":"Indian J Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ophtha.2016.10.040","article-title":"Intraocular hemorrhages and retinopathy of prematurity in the telemedicine approaches to evaluating acute-phase retinopathy of prematurity (e-ROP) study","volume":"124","author":"Daniel","year":"2017","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12886-018-0815-1","article-title":"Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner","year":"2016","journal-title":"Ophthalmology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5078565","DOI":"10.1155\/2017\/5078565","article-title":"Recurrence of retinopathy of prematurity in zone II stage 3+after ranibizumab treatment: a retrospective study","volume":"2017","author":"Hu","year":"2017","journal-title":"J Ophthalmol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1440437\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T07:19:31Z","timestamp":1736234371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1440437\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":37,"alternative-id":["10.3389\/fped.2024.1440437"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1440437","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2025,1,7]]},"article-number":"1440437"}}